Death at 28 days · CRRT
Citrate showed no clear difference in death at 28 days compared with unfractionated heparin (moderate certainty).
1 finding from 1 review
Death (any cause) · patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) · patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (3.0 mg/kg) changes death (any cause) compared with placebo (very low certainty).
1 finding from 1 review
Death (any cause) · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (1.0 mg/kg) changes death (any cause) compared with placebo (very low certainty).
1 finding from 1 review
Death (any cause) · patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Death at one year · adults with renal vasculitis
The intervention showed no clear difference in death at one year (low certainty).
1 finding from 1 review
Death at 6 months · adults with renal vasculitis
Rituximab showed no clear difference in death at 6 months compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Death at 6 months · adults with renal vasculitis
Mycophenolate mofetil showed no clear difference in death at 6 months compared with cyclophosphamide (low certainty).
1 finding from 1 review
Death at 6 months · adults with renal vasculitis for maintenance therapy
Antibiotics showed no clear difference in death at 6 months compared with placebo (low certainty).
1 finding from 1 review
Death (any cause) · heart failure with chronic kidney disease
ACUTE: Serelaxin showed no clear difference in death (any cause) compared with placebo (low certainty).
1 finding from 1 review
Death (any cause) · people with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) · people with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) · people with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (all causes) · preventing bone disease in kidney transplant recipients
It is very uncertain whether vitamin D changes death (all causes) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Death (all causes) · preventing bone disease in kidney transplant recipients
It is very uncertain whether bisphosphonate changes death (all causes) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Death (any cause) ( · heart failure with chronic kidney disease
CHRONIC: ACEi or ARB showed no clear difference in death (any cause) ( compared with placebo (low certainty).
1 finding from 1 review
Death (any cause) ( · heart failure with chronic kidney disease
CHRONIC: Beta‐blockers probably leads to lower death (any cause) ( compared with placebo (moderate certainty).
1 finding from 1 review
Death (any cause) ( · heart failure with chronic kidney disease
It is very uncertain whether CHRONIC: Aldosterone antagonists changes death (any cause) ( compared with placebo (very low certainty).
1 finding from 1 review
Death from any cause · AKI patients receiving CKRT
It is very uncertain whether CVVHD changes death from any cause compared with CVVH or CVVHDF (very low certainty).
1 finding from 1 review